Global Human Microbiome Market

1 INTRODUCTION OF GLOBAL HUMAN MICROBIOMEMARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HUMAN MICROBIOMEMARKETOUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework
5 GLOBAL HUMAN MICROBIOME MARKET, BY PRODUCT
5.1 Instruments
5.1.1 Laboratory Instruments
5.1.2 Analyzers
5.2 Consumables
5.2.1 Kits
5.2.2 Reagents

6 GLOBAL HUMAN MICROBIOME MARKET, BY TECHNOLOGY
6.1 Cell Culture Technology
6.2 High-Throughput Technology
6.3 Omics Technology
6.4 Computational Tools

7 GLOBAL HUMAN MICROBIOME MARKET, BY DISEASE
7.1 Acute Diarrhea
7.2 Obesity
7.3 Diabetes
7.4 Autoimmune Disorders
7.5 Cancer
7.6 Mental Disorders
7.7 Other Diseases

8 GLOBAL HUMAN MICROBIOME MARKET, BY APPLICATION
8.1 Therapeutics
8.2 Diagnostics

9 GLOBAL HUMAN MICROBIOME MARKET, BY PRODUCT TYPE
9.1 Probiotics
9.2 Foods
9.3 Prebiotics
9.4 Medical Foods
9.5 Diagnostic Devices
9.6 Drugs
9.7 Other Probiotic Supplements
10 GLOBAL HUMAN MICROBIOMEMARKET, BY GEOGRAPHY
10.1 Overview
10.2 North AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.2.1 U.S.
10.2.2 Canada
10.2.3 Mexico
10.3 EuropeRegional Market Estimates and Forecasts, 2012 - 2025
10.3.1 Germany
10.3.2 U.K.
10.3.3 France
10.3.4 Rest of Europe
10.4 Asia PacificRegional Market Estimates and Forecasts, 2012 - 2025
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of Asia Pacific
10.5 Latin AmericaRegional Market Estimates and Forecasts, 2012 - 2025
10.5.1 Brazil
10.5.2 Argentina
10.6 Rest of the WorldRegional Market Estimates and Forecasts, 2012 - 2025

11 GLOBAL HUMAN MICROBIOMEMARKETCOMPETITIVE LANDSCAPE
11.1 Overview
11.2 Company Market Share
11.3 Vendor Landscape
11.4 Key Development Strategies

12 COMPANY PROFILES
12.1 Enterome Bioscience
12.1.1 Overview
12.1.2 Financial Performance
12.1.3 Product Outlook
12.1.4 Key Developments

12.2 E.I. Du Pont De Nemours and Company
12.2.1 Overview
12.2.2 Financial Performance
12.2.3 Product Outlook
12.2.4 Key Developments

12.3 Merck & Co., Inc.
12.3.1 Overview
12.3.2 Financial Performance
12.3.3 Product Outlook
12.3.4 Key Developments

12.4 Metabiomics Corporation
12.4.1 Overview
12.4.2 Financial Performance
12.4.3 Product Outlook
12.4.4 Key Developments

12.5 Yakult Honsha Co., Ltd.
12.5.1 Overview
12.5.2 Financial Performance
12.5.3 Product Outlook
12.5.4 Key Developments

12.6 Microbiome Therapeutics, LLC
12.6.1 Overview
12.6.2 Financial Performance
12.6.3 Product Outlook
12.6.4 Key Developments

12.7 Osel, Inc.
12.7.1 Overview
12.7.2 Financial Performance
12.7.3 Product Outlook
12.7.4 Key Developments

12.8 Second Genome, Inc.
12.8.1 Overview
12.8.2 Financial Performance
12.8.3 Product Outlook
12.8.4 Key Developments

12.9 Vithera Pharmaceuticals
12.9.1 Overview
12.9.2 Financial Performance
12.9.3 Product Outlook
12.9.4 Key Developments

12.10 Vedanta Biosciences, Inc.
12.10.1 Overview
12.10.2 Financial Performance
12.10.3 Product Outlook
12.10.4 Key Developments

13 Appendix
13.1 Related Reports